Submissions for variant NM_024675.4(PALB2):c.25C>T (p.Leu9Phe)

dbSNP: rs1060502744

Total submissions: 9

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Labcorp Genetics (formerly Invitae), Labcorp	RCV000464168	SCV000550639	uncertain significance	Familial cancer of breast	2023-12-31	criteria provided, single submitter	clinical testing	This sequence change replaces leucine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 9 of the PALB2 protein (p.Leu9Phe). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with PALB2-related cancer (PMID: 30287823, 35171259). ClinVar contains an entry for this variant (Variation ID: 410124). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics	RCV000566603	SCV000666870	uncertain significance	Hereditary cancer-predisposing syndrome	2024-01-25	criteria provided, single submitter	clinical testing	The p.L9F variant (also known as c.25C>T), located in coding exon 1 of the PALB2 gene, results from a C to T substitution at nucleotide position 25. The leucine at codon 9 is replaced by phenylalanine, an amino acid with highly similar properties. This alteration has been reported with a carrier frequency of 0.00071 in 7051 unselected breast cancer patients and 0.00107 in 11241 female controls of Japanese ancestry (Momozawa Y et al. Nat Commun, 2018 10;9:4083). This alteration was also identified in 1 of 1009 patients amongst a cohort of Chinese patients with a personal history of pancreatic ductal adenocarcinoma (Yin L et al. JAMA Netw Open, 2022 Feb;5:e2148721). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear.
Counsyl	RCV000464168	SCV000786594	uncertain significance	Familial cancer of breast	2018-06-05	criteria provided, single submitter	clinical testing
Cancer Genomics Group, Japanese Foundation For Cancer Research	RCV001030718	SCV001193686	uncertain significance	Hereditary breast ovarian cancer syndrome	2019-05-01	criteria provided, single submitter	research
GeneDx	RCV001030103	SCV002005460	uncertain significance	not provided	2020-10-06	criteria provided, single submitter	clinical testing	Reported as a variant of uncertain significance in the published literature; identified in Japanese individuals with breast cancer as well as Japanese control individuals in a case-control study (Momozawa et al., 2018); In silico analysis supports that this missense variant does not alter protein structure/function; Not observed in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 32566746, 30287823)
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV002282156	SCV002572147	uncertain significance	not specified	2022-08-18	criteria provided, single submitter	clinical testing	Variant summary: PALB2 c.25C>T (p.Leu9Phe) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant was absent in 247890 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.25C>T has been reported in the literature as a VUS in settings of multigene panel testing among individuals with Breast Cancer as well as unaffected controls (example, Momozawa_2018). This report does not provide unequivocal conclusions about association of the variant with Breast Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six submitters have provided clinical-significance assessments for this variant to ClinVar after 2014 and all classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
Myriad Genetics, Inc.	RCV000464168	SCV004019189	uncertain significance	Familial cancer of breast	2023-03-30	criteria provided, single submitter	clinical testing	This variant is classified as a variant of uncertain significance as there is insufficient evidence to determine its impact on protein function and/or cancer risk.
Baylor Genetics	RCV000464168	SCV005055037	uncertain significance	Familial cancer of breast	2023-11-22	criteria provided, single submitter	clinical testing
Leiden Open Variation Database	RCV001030103	SCV001192902	uncertain significance	not provided	2018-10-10	no assertion criteria provided	curation	Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitter to LOVD: Yukihide Momozawa.